Tzield™ (teplizumab-mzwv) – New drug approval
November 17, 2022 - The FDA announced the approval of Provention Bio’s Tzield (teplizumab-mzwv), to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with Stage 2 T1D.
Download PDF
